Orforglipron – Oral GLP-1 Receptor Agonist

Orforglipron is the first non-peptide GLP-1 receptor agonist (GLP-1RA) designed for once-daily oral administration. It improves glycemic control and supports meaningful weight reduction by:
Enhancing glucose-dependent insulin secretion
Suppressing glucagon release
Slowing gastric emptying
Promoting satiety
 
Unlike injectable GLP-1 therapies, Orforglipron is taken orally without food or water restrictions, offering a convenient alternative to expand patient access and support long-term adherence.